Protein / target

Killer cell immunoglobulin-like receptor 2DL2

KIR2DL2P43627Homo sapiensSwiss-Prot
UniProt: P43627Ensembl: ENSG00000275546HGNC: HGNC:6330NCBI Gene: 3803
11
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Transmembrane signaling receptor activity

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Receptor on natural killer (NK) cells for HLA-Cw1, 3, 7, and 8 allotypes. Inhibits the activity of NK cells thus preventing cell lysis

Subcellular location

Cell membrane
Domains and Gene Ontology detail (6)

Domains & features

Ig-like C2-type 1Ig-like C2-type 2

Gene Ontology

  • Cplasma membrane
  • Fimmune receptor activity
  • Ftransmembrane signaling receptor activity
  • Pimmune response-inhibiting cell surface receptor signaling pathway

348 aa · 38 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingGO
View supporting evidence

Immune signalling

  • ·immune response-inhibiting cell surface receptor signaling pathway
View underlying pathways (1)
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

lirilumab
Narrow target profileInhibitor

Killer cell immunoglobulin-like receptor 2DL2 inhibitor

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Clinical trials

11

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid TumorsPHASE1/PHASE2

COMPLETED · via lirilumab · NCT01714739

Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)PHASE2

COMPLETED · via lirilumab · NCT02481297

A Phase 1 Study of the Safety and Pharmacokinetics of Anti-KIR Monoclonal Antibody (Lirilumab, BMS-986015) in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab,BMS-936558) or in Combination With Nivolumab and Anti-CTLA-4 Monoclonal Antibody (Ipilimumab, BMS-734016) in Advanced and/or Metastatic Solid TumorsPHASE1

COMPLETED · via lirilumab · NCT03203876

A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid TumorsPHASE1

COMPLETED · via lirilumab · NCT01750580

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)PHASE1/PHASE2

TERMINATED · via lirilumab · NCT03347123

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and NeckPHASE2

ACTIVE_NOT_RECRUITING · via lirilumab · NCT03341936

Show remaining trials (5)
An Open-Label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid LeukemiaPHASE2

TERMINATED · via lirilumab · NCT02399917

A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaPHASE1

COMPLETED · via lirilumab · NCT02252263

Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic MalignanciesPHASE1/PHASE2

COMPLETED · via lirilumab · NCT01592370

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsPHASE1/PHASE2

RECRUITING · via lirilumab · NCT02813135

Phase II Combination of Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)PHASE2

TERMINATED · via lirilumab · NCT02599649

ClinicalTrials.gov via the drug-target graph.

What's happening now

1

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. New publication2024-01-07
    Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab.

    Scientific reports · 2024 · 7 citations · Europe PMC · via lirilumab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.